Sanofi's Financial Growth Highlights

Sanofi SA announced a remarkable annual increase of 10.8% in its net sales for the first quarter of fiscal year 2025, amounting to €9.9 billion. This growth reflects the company's strong performance and resilience in a dynamic market environment.

Financial Performance Details

The company's net income, under the International Financial Reporting Standards (IFRS), was reported at €1.8 billion, with an IFRS earnings per share (EPS) of €1.52. Notably, Sanofi's business net income witnessed a 15.9% increase, or 14.5% at the constant exchange rate (CER), reaching €2.2 million. The business EPS also saw a significant rise of 17%, or 15.7% at CER, to €1.79.

Gross Profit and Future Outlook

Sanofi's gross profit soared by 14.2%, or 11.3% at CER, to €7.7 billion in the first quarter. CEO Paul Hudson expressed confidence in the company's trajectory, stating, "Underpinned by the growth in sales and business EPS, we confirm our 2025 guidance with the knowledge of the external environment we have today."